Recursion Pharmaceuticals is trying to solve a serious problem. Even with technological improvements, the time and costs required to develop brand-new drugs have increased in recent decades. It can ...

Pine cones. Stock-market quotations. Sunflowers. Classical architecture. Reproduction of bees. Roman poetry. What do they have in common? In one way or another, these and many more creations of nature ...

Recursion Pharmaceuticals (RXRX) added ~11% in the morning trading on Wednesday after J.P. Morgan upgraded the AI-driven biotech to Overweight from Neutral, citing a blockbuster sales potential for ...

Andrew covers the biopharma industry, scientific research, and public health across the continent. You can reach Andrew confidentially on Signal at drewqjoseph.71. LONDON — In the year-plus since ...

After 12 years leading Utah-based techbio company Recursion, CEO Chris Gibson is stepping down. Recursion’s R&D head and Chief Commercial Officer Najat Khan will become CEO effective Jan. 1. Gibson co ...

According to @TATrader_Alan, the DOGE daily chart shows the Fibonacci 0.382 retracement acting as solid support with multiple price rejections at that zone, highlighting a key support level traders ...

A must-read for FX traders! Fibonacci analysis is not just a technical indicator, but a powerful tool for uncovering the essence of the market. Don't you want to know the advanced techniques actually ...

As of March 31, Recursion Pharmaceuticals had a cash position of $509 million. Following Tuesday’s layoffs, the biotech expects its runway to last into the fourth quarter of 2027. Recursion ...